LITHOBID (lithium carbonate) by ANI Pharmaceuticals is 12. First approved in 1979.
Drug data last refreshed 2d ago
LITHOBID (lithium carbonate) is an oral extended-release mood stabilizer indicated for bipolar disorder, acute bipolar depression, major depressive disorder, and treatment-resistant depression. The mechanism of action remains unknown, but lithium is completely absorbed in the upper GI tract with peak serum concentrations occurring 2-6 hours post-dose. It is not metabolized and is primarily excreted unchanged in urine with an elimination half-life of 18-36 hours.
Product is in late-stage lifecycle with minimal Medicare spending and very limited claims volume, indicating a small team focused on maintenance rather than expansion.
12.1 Mechanism of Action The mechanism of action of lithium as a mood stabilizing agent is unknown. 12.3 Pharmacokinetics Absorption After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T max ) occur 0.25 to 3 hours…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects
Worked on LITHOBID at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLITHOBID has zero linked job postings, indicating minimal hiring activity and limited career openings. This legacy product with approaching LOE offers constrained opportunities for brand building, field sales, or medical affairs expansion.